|
1
|
Lim H, Devesa SS, Sosa JA, Check D and
Kitahara CM: Trends in thyroid cancer incidence and mortality in
the United States, 1974–2013. JAMA. 317:1338–1348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dal Maso L, Tavilla A, Pacini F, Serraino
D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna
M, Agius D, et al: Survival of 86,690 patients with thyroid cancer:
A population-based study in 29 European countries from EUROCARE-5.
Eur J Cancer. 77:140–152. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sparano C, Moog S, Hadoux J, Dupuy C, Al
Ghuzlan A, Breuskin I, Guerlain J, Hartl D, Baudin E and Lamartina
L: Strategies for radioiodine treatment: What's new. Cancers
(Basel). 14:38002022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin Y, Van Nostrand D, Cheng L, Liu M and
Chen L: Radioiodine refractory differentiated thyroid cancer. Crit
Rev Oncol Hematol. 125:111–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mu ZZ, Zhang X and Lin YS: Identification
of radioactive iodine refractory differentiated thyroid cancer.
Chonnam Med J. 55:1272019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu Q, Zhang X, Li L, Zhang C, Huang J and
Huang W: Molecular basis and targeted therapies for radioiodine
refractory thyroid cancer. Asia Pac J Clin Oncol. 10:ajco.13836.
2022.
|
|
8
|
Jögi A, Vaapil M, Johansson M and Påhlman
S: Cancer cell differentiation heterogeneity and aggressive
behavior in solid tumors. Ups J Med Sci. 117:217–224. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haugen BR, Alexander EK, Bible KC, Doherty
GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM,
Schlumberger M, et al: 2015 American thyroid association management
guidelines for adult patients with thyroid nodules and
differentiated thyroid cancer: The american thyroid association
guidelines task force on thyroid nodules and differentiated thyroid
cancer. Thyroid. 26:1–133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pirooznia N, Abdi K, Beiki D, Emami F,
Arab SS, Sabzevari O and Soltani-Gooshkhaneh S: 177Lu-labeled
cyclic RGD peptide as an imaging and targeted radionuclide
therapeutic agent in non-small cell lung cancer: Biological
evaluation and preclinical study. Bioorg Chem. 102:1041002020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schuchardt C, Zhang J, Kulkarni HR, Chen
X, Müller D and Baum RP: Prostate-specific membrane antigen
radioligand therapy using 177 Lu-PSMA I&T and
177 Lu-PSMA-617 in patients with metastatic
castration-resistant prostate cancer: Comparison of safety,
biodistribution, and dosimetry. J Nucl Med. 63:1199–1207. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai G, Levy O and Carrasco N: Cloning and
characterization of the thyroid iodide transporter. Nature.
379:458–460. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Paladino S and Melillo RM: Editorial:
Novel mechanism of radioactive iodine refractivity in thyroid
cancer. J Natl Cancer Inst. 109:10.1093/jnci/djx106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo G, Zhou J, Li G, Hu N, Xia X and Zhou
H: Retracted: Ferruginol diterpenoid selectively inhibits human
thyroid cancer growth by inducing mitochondrial dependent
apoptosis, endogenous reactive oxygen species (ROS) production,
mitochondrial membrane potential loss and suppression of
mitogen-activated protein kinase (MAPK) and PI3K/AKT signaling
pathways. Med Sci Monit. 27:e9323412021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ban Z, He J, Tang Z, Zhang L and Xu Z:
LRG-1 enhances the migration of thyroid carcinoma cells through
promotion of the epithelial-mesenchymal transition by activating
MAPK/p38 signaling. Oncol Rep. 41:3270–3280. 2019.PubMed/NCBI
|
|
16
|
Li W, Qian C, Ma F, Liu M, Sun X, Liu X,
Liu C, Chen Z, Ma W, Liu J, et al: MAPK/ERK-CBP-RFPL-3 mediates
adipose-derived stem cell-induced tumor growth in breast cancer
cells by activating telomerase reverse transcriptase expression.
Stem Cells Int. 2022:85405352022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahmed AA, Farooqi MS, Habeebu SS, Gonzalez
E, Flatt TG, Wilson AL and Barr FG: NanoString digital molecular
profiling of protein and microrna in rhabdomyosarcoma. Cancers
(Basel). 14:5222022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Zhang R, Liu F, Jiang P, Xu J, Cao
H, Du X, Ma L, Lin F, Cheng L, et al: TMT-based quantitative
proteomic analysis reveals proteomic changes involved in longevity.
Prot Clin Appl. 13:18000242019. View Article : Google Scholar
|
|
19
|
Kroksveen AC, Aasebø E, Vethe H, Van Pesch
V, Franciotta D, Teunissen CE, Ulvik RJ, Vedeler C, Myhr KM,
Barsnes H and Berven FS: Discovery and initial verification of
differentially abundant proteins between multiple sclerosis
patients and controls using iTRAQ and SID-SRM. J Proteomics.
78:312–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li XJ, Pan HT, Chen JJ, Fu YB, Fang M, He
GH, Zhang T, Ding HG, Yu B, Cheng Y, et al: Proteomics of
uterosacral ligament connective tissue from women with and without
pelvic organ prolapse. Prot Clin Appl. 13:18000862019. View Article : Google Scholar
|
|
21
|
Zhou Y, Lih TM, Pan J, Höti N, Dong M, Cao
L, Hu Y, Cho KC, Chen SY, Eguez RV, et al: Proteomic signatures of
16 major types of human cancer reveal universal and
cancer-type-specific proteins for the identification of potential
therapeutic targets. J Hematol Oncol. 13:1702020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang JH, Lin Y, Ouyang T, Tang W, Huang
Y, Ye W, Zhao JY, Wang ZN and Ma CC: Nuclear magnetic
resonance-based metabolomics and metabolic pathway networks from
patient-matched esophageal carcinoma, adjacent noncancerous tissues
and urine. World J Gastroenterol. 25:3218–3230. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukui R, Saga R, Matsuya Y, Tomita K,
Kuwahara Y, Ohuchi K, Sato T, Okumura K, Date H and Fukumoto M:
Tumor radioresistance caused by radiation-induced changes of
stem-like cell content and sub-lethal damage repair capability. Sci
Rep. 12:10562022. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Suwiwat S, Tungsinmunlong K and
Siriaungkul S: Expression of CD44v6 and RCAS1 in uterine cervical
carcinoma infected with human papillomavirus and its effect on cell
proliferation and differentiation. Asian Pac J Cancer Prev.
23:2431–2439. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui Y, Liu Y, Mu L, Li Y and Wu G:
Transcriptional expressions of ALDH1A1/B1 as independent indicators
for the survival of thyroid cancer patients. Front Oncol.
12:8219582022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ravera S, Reyna-Neyra A, Ferrandino G,
Amzel LM and Carrasco N: The Sodium/Iodide Symporter (NIS):
Molecular physiology and preclinical and clinical applications.
Annu Rev Physiol. 79:261–289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Z, Zhou Q, Li A, Huang W, Cai Z and
Chen W: Extracellular matrix protein 1 (ECM1) is associated with
carcinogenesis potential of human bladder cancer. Onco Targets
Ther. 12:1423–1432. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feng M, Dong N, Zhou X, Ma L and Xiang R:
Myosin light chain 9 promotes the proliferation, invasion,
migration and angiogenesis of colorectal cancer cells by binding to
Yes-associated protein 1 and regulating Hippo signaling.
Bioengineered. 13:96–106. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo D, Chen H, Lu P, Li X, Long M, Peng X,
Huang M, Huang K, Lin S, Tan L, et al: CHI3L1 overexpression is
associated with metastasis and is an indicator of poor prognosis in
papillary thyroid carcinoma. Cancer Biomark. 18:273–284. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dimitrova I, Shinkov A, Dodova R, Ivanova
R, Kirilov G, Kyurkchiyan S, Kaneva R and Kovatcheva R: Increased
gene expression of TIMP1 and CHI3L1 in fine-needle aspiration
biopsy samples from papillary thyroid cancer as compared to benign
nodules. Diagn Cytopathol. 49:1045–1051. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moore RG, Blackman A, Miller MC, Robison
K, DiSilvestro PA, Eklund EK, Strongin R and Messerlian G: Multiple
biomarker algorithms to predict epithelial ovarian cancer in women
with a pelvic mass: Can additional makers improve performance?
Gynecol Oncol. 154:150–155. 2019. View Article : Google Scholar : PubMed/NCBI
|
